Skip to Content

Merck & Co Inc

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Merck Earnings: Strong Overall Growth Led by Keytruda Supports Fair Value Increase

We are increasing Merck's fair value estimate to $120 from $114 based on strong first-quarter results that ran ahead of our expectations combined with a pipeline that is progressing well.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of MRK so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center